Chevron Ruling Could Chill FDA’s Public Health Efforts, Stem AI, LDT Regulation

By Jessica Karins, Sigi Ris / June 28, 2024 at 6:10 PM
The Supreme Court’s decision Friday (June 28) overturning the Chevron doctrine could force FDA to spend more time considering the political and legal environment surrounding regulatory efforts -- hamstringing its ability to take bold action on public health priorities -- given that courts can no longer defer to federal agencies’ interpretation of vague statutes, regulatory experts say. Reshma Ramachandran, assistant professor at Yale School of Medicine, said the decision will be a major obstacle to FDA as it grapples...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.